New Dual-Action antibody takes on Hard-to-Treat cancers
NCT ID NCT04140500
First seen Oct 31, 2025 · Last updated Apr 22, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will receive the drug. The main goals are to find the safest dose and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adana City Hospital, Medical Oncology
Adana, 01060, Turkey (Türkiye)
-
Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center
Yen?mahalle, 06200, Turkey (Türkiye)
-
Ankara City Hospital
Ankara, 06800, Turkey (Türkiye)
-
Asan Medical Center
Seoul, 05505, South Korea
-
Chaim Sheba medical center, Oncology division
Ramat Gan, 5262000, Israel
-
Christie Hospital NHS Trust
Manchester, M20 4BX, United Kingdom
-
Clinica Universidad de Navarra Madrid
Madrid, 28027, Spain
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Consultorio Médico Jordi Guzmán Casta
Querétaro City, Querétaro, 76226, Mexico
-
Hacettepe Uni Medical Faculty Hospital
Sihhiye/Ankara, 06230, Turkey (Türkiye)
-
Hadassah University Hospital - Ein Kerem
Jerusaelm, 9112001, Israel
-
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, 44280, Mexico
-
Inst. Nacional de Cancerología
Mexico City, Mexico CITY (federal District), 14080, Mexico
-
LLC Arensia Explorer Medicine
Tbilisi, 0112, Georgia
-
National Cancer Centre
Singapore, 169610, Singapore
-
National University Hospital
Singapore, 119228, Singapore
-
Odense Universitetshospital, Onkologisk Afdeling R
Odense C, 5000, Denmark
-
Queen Elizabeth Hospital
Birmingham, B15 2TH, United Kingdom
-
Rabin MC
Petah Tikva, 4941492, Israel
-
Rigshospitalet
København Ø, 2100, Denmark
-
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
START Madrid. Centro Integral Oncologico Clara Campal
Madrid, 28050, Spain
-
Seoul National University Bundang Hospital
Seongnam-si, 13605, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.